Dave Nellesen

682 total citations
27 papers, 457 citations indexed

About

Dave Nellesen is a scholar working on Surgery, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dave Nellesen has authored 27 papers receiving a total of 457 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Surgery, 5 papers in Genetics and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dave Nellesen's work include Lymphoma Diagnosis and Treatment (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Pituitary Gland Disorders and Treatments (3 papers). Dave Nellesen is often cited by papers focused on Lymphoma Diagnosis and Treatment (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Pituitary Gland Disorders and Treatments (3 papers). Dave Nellesen collaborates with scholars based in United States, United Kingdom and Switzerland. Dave Nellesen's co-authors include Anita Chawla, Robyn T. Carson, Barbara Edelman Lewis, RN, Bernard J. Lavins, Debora L. Oh, Maureen P. Neary, W.H. Ludlam, Soyon Lee and Jincy Paulose and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Oncotarget.

In The Last Decade

Dave Nellesen

25 papers receiving 442 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dave Nellesen United States	9	223	148	49	45	42	27	457
Akash Patel United States	12	42 0.2×	64 0.4×	88 1.8×	19 0.4×	64 1.5×	28	337
Robin Owen United Kingdom	11	102 0.5×	69 0.5×	17 0.3×	42 0.9×	39 0.9×	25	586
Katherine Jones United Kingdom	11	20 0.1×	59 0.4×	32 0.7×	39 0.9×	93 2.2×	31	477
Michelle Duong United States	10	25 0.1×	118 0.8×	69 1.4×	15 0.3×	78 1.9×	13	586
Cheryl L. Wright United States	11	91 0.4×	236 1.6×	29 0.6×	5 0.1×	27 0.6×	19	630
Peter Lambert United States	14	62 0.3×	234 1.6×	53 1.1×	10 0.2×	36 0.9×	40	682
Christopher D. Jolley United States	12	62 0.3×	181 1.2×	31 0.6×	4 0.1×	85 2.0×	20	407
Roberto Franceschi Italy	13	42 0.2×	125 0.8×	48 1.0×	7 0.2×	92 2.2×	68	567
Adrijana D’Silva Canada	12	77 0.3×	31 0.2×	95 1.9×	2 0.0×	30 0.7×	34	433
Akihiro Tokoro Japan	12	47 0.2×	44 0.3×	64 1.3×	7 0.2×	31 0.7×	33	365

Countries citing papers authored by Dave Nellesen

Since Specialization

Citations

This map shows the geographic impact of Dave Nellesen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dave Nellesen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dave Nellesen more than expected).

Fields of papers citing papers by Dave Nellesen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dave Nellesen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dave Nellesen. The network helps show where Dave Nellesen may publish in the future.

Co-authorship network of co-authors of Dave Nellesen

This figure shows the co-authorship network connecting the top 25 collaborators of Dave Nellesen. A scholar is included among the top collaborators of Dave Nellesen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dave Nellesen. Dave Nellesen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Desai, Urvi, et al.. (2024). Public sector replacement of privately funded pharmaceutical R&D: cost and efficiency considerations. Journal of Medical Economics. 27(1). 1253–1266. 1 indexed citations

Curigliano, Giuseppe, Eva Ciruelos, Kevin Kalinsky, et al.. (2024). Short-term risk of recurrence in patients (pts) with HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in randomized clinical trials (RCTs): A meta-analysis.. Journal of Clinical Oncology. 42(16_suppl). 541–541. 9 indexed citations

Lee, Soyon, et al.. (2022). Burden of central nervous system complications in sickle cell disease: A systematic review and meta‐analysis. Pediatric Blood & Cancer. 69(4). e29493–e29493. 5 indexed citations

Nellesen, Dave, et al.. (2022). A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib. Advances in Therapy. 39(4). 1678–1696. 5 indexed citations

Nellesen, Dave, et al.. (2022). Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score-matched analysis of E7438-G000-101 trial outcomes. Oncotarget. 13(1). 677–683. 9 indexed citations

Waheed, Anem, et al.. (2022). A Systematic Literature Review of Clinical and Economic Outcomes for Patients with Paroxysmal Nocturnal Hemoglobinuria in Clinical Trials and Real-World Settings. Blood. 140(Supplement 1). 11451–11452. 2 indexed citations

Zaidi, Ahmar U., Soyon Lee, Eric Morris, et al.. (2021). A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease. Orphanet Journal of Rare Diseases. 16(1). 460–460. 28 indexed citations

RN, et al.. (2021). The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers. PharmacoEconomics. 39(6). 619–625. 92 indexed citations

Gaballa, Sameh, et al.. (2021). Health care cost impact associated with adverse events (AEs) among treatments in third-line+ (3L+) relapsed/refractory follicular lymphoma (R/R FL).. Journal of Clinical Oncology. 39(15_suppl). e18836–e18836.

10.

Miller, Aaron, et al.. (2020). PCN84 BUDGET IMPACT ANALYSIS OF AYVAKIT (AVAPRITINIB) IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS AND A PDGFRA EXON 18 MUTATION. Value in Health. 23. S38–S38. 1 indexed citations

11.

Nellesen, Dave, et al.. (2020). Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A Matching-Adjusted Indirect Comparison of Single-Arm Trials. Blood. 136(Supplement 1). 16–16. 1 indexed citations

12.

Nellesen, Dave, et al.. (2018). Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer (NSCLC) in the United States. Value in Health. 21. S175–S175.

13.

Brown, Jacqueline, et al.. (2016). Management of epidermal growth factor receptor inhibitor-associated rash: a systematic review. The Journal of Community and Supportive Oncology. 14(1). 21–28. 15 indexed citations

14.

Nellesen, Dave, et al.. (2016). Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic. Journal of Medical Economics. 20(4). 395–404. 5 indexed citations

15.

Nellesen, Dave, et al.. (2015). Budget impact of pasireotide LAR for the treatment of acromegaly, a rare endocrine disorder. Journal of Medical Economics. 19(4). 374–384. 8 indexed citations

16.

Nellesen, Dave, Hong Truong, Maureen P. Neary, & W.H. Ludlam. (2015). Economic burden of multiple chronic comorbidities associated with Cushing’s disease, a rare endocrine disorder. Expert Opinion on Orphan Drugs. 4(3). 291–297. 4 indexed citations

17.

Truong, Hong, Dave Nellesen, W.H. Ludlam, & Maureen P. Neary. (2014). Budget impact of pasireotide for the treatment of Cushing’s disease, a rare endocrine disorder associated with considerable comorbidities. Journal of Medical Economics. 17(4). 288–295. 9 indexed citations

18.

Nellesen, Dave, et al.. (2013). Comorbidities in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation: A Review of the Literature From the Past Decade. Postgraduate Medicine. 125(2). 40–50. 51 indexed citations

19.

Nellesen, Dave, et al.. (2013). A Systematic Review of the Economic and Humanistic Burden of Illness in Irritable Bowel Syndrome and Chronic Constipation. Journal of Managed Care Pharmacy. 19(9). 755–764. 192 indexed citations

20.

Chawla, Anita, Amit M. Oza, Dave Nellesen, et al.. (2012). PCN148 Review of National Institute for Health and Clinical Excellence (NICE) Recommendations for Anti-Cancer Agents Across Multiple Drug-Indication Combinations. Value in Health. 15(7). A436–A436. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact